EU wants data on heart inflammation, but European Commission also approves Merck's marketing authorization for soluble guanylate cyclase (sGC) stimulator VERQUVO® (vericiguat).
In the EU, VERQUVO (2.5 mg, 5 mg, and 10 mg) is indicated for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilized after a recent decompensation event requiring intravenous (IV) therapy. VERQUVO is being jointly developed by Merck and Bayer AG. Merck has the commercial rights to VERQUVO in the United States and Bayer has the exclusive commercial rights in the rest of world.
Exposing medical crime as WITCHCRAFT: Vaccines are medical SORCERY